Table of Contents
Leukemia Research and Treatment
Volume 2013, Article ID 275760, 14 pages
http://dx.doi.org/10.1155/2013/275760
Review Article

The Impact of FLT3 Mutations on the Development of Acute Myeloid Leukemias

Department of Hematology, Oncology and Molecular Medicine, Upper Health Institute, Viale Regina Elena 299, 00161 Rome, Italy

Received 1 February 2013; Revised 30 April 2013; Accepted 14 May 2013

Academic Editor: Monique den Boer

Copyright © 2013 Ugo Testa and Elvira Pelosi. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Citations to this Article [3 citations]

The following is the list of published articles that have cited the current article.

  • Roni Shouval, Liran I. Shlush, Shlomit Yehudai-Resheff, Shahnaz Ali, Neta Pery, Ehud Shapiro, Maty Tzukerman, Jacob M. Rowe, and Tsila Zuckerman, “Single cell analysis exposes intratumor heterogeneity and suggests that FLT3-ITD is a late event in leukemogenesis,” Experimental Hematology, vol. 42, no. 6, pp. 457–463, 2014. View at Publisher · View at Google Scholar
  • Ewa Augustin, Anna Skwarska, Anna Weryszko, Iwona Pelikant, Ewa Sankowska, and Barbara Borowa-Mazgaj, “The antitumor compound triazoloacridinone C-1305 inhibits FLT3 kinase activity and potentiates apoptosis in mutant FLT3-ITD leukemia cells,” Acta Pharmacologica Sinica, vol. 36, no. 3, pp. 385–399, 2015. View at Publisher · View at Google Scholar
  • John E Bisi, Jessica A Sorrentino, Jamie L Jordan, David D Darr, Patrick J Roberts, Francis X Tavares, and Jay C Strum, “Preclinical development of G1T38: A novel, potent and selective inhibitor of cyclin dependent kinases 4/6 for use as an oral antineoplastic in patients with CDK4/6 sensitive tumors.,” Oncotarget, vol. 8, no. 26, pp. 42343–42358, 2017. View at Publisher · View at Google Scholar